Supplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Supplemental Table 3: Baseline characteristics of patients with de novo BRAF fusions treated with MAPK-pathway directed therapies.